Brief: Cocrystal Pharma’s CC-42344 Shows Strong Antiviral Potency Against 2024 H5n1 Avian Influenza Strain
29/05/2025 13:28
May 29 (Reuters) - Cocrystal Pharma Inc COCP.O: COCRYSTAL PHARMA’S INVESTIGATIONAL DRUG CANDIDATE CC-42344 DEMONSTRATES STRONG ANTIVIRAL POTENCY AGAINST THE 2024 HIGHLY PATHOGENIC H5N1 AVIAN INFLUENZA STRAIN Source text: ID:nGNX1vmqXg Further company coverage: COCP.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cocrystal Pharma
See all newsBrief: Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Human Challenge Study Evaluating CDI-988 For Norovirus Prevention And Treatment
Cocrystal Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Cocrystal Pharma Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway